{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009364","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.280568+00:00","generated_at":"2026-05-22T01:34:46.386835+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InspireMD Q1 net loss widens to $0.22/sh; FDA approval of CGuard Prime expected Q3 2025","bullets":["Revenue $1.529M (+1.2% YoY); net loss $11.166M ($0.22/sh) vs $7.032M loss ($0.21/sh) in Q1 2024.","Operating expenses rose 52.5% to $11.752M on U.S. sales force build and CGuard Prime launch preparation.","Cash and securities $26.086M at March 31, down from $34.637M at Dec 31, 2024.","FDA PMA for CGuard Prime carotid stent system anticipated in Q3 2025; commercial team in place."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009364","json":"https://secwatch.observer/filing/0001641172-25-009364.json","markdown":"https://secwatch.observer/filing/0001641172-25-009364.md","text":"https://secwatch.observer/filing/0001641172-25-009364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000164117225009364/0001641172-25-009364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000164117225009364/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:34:46.386835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}